Veracyte, Inc.
VCYT
Ранг среди акций
#4350
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Цена акции
$44.93
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$3.61B
Изменение (1 день)
2.57%
Изменение (1 год)
24.45%
Страна
US
Торговля Veracyte, Inc. (VCYT)
Категория
Healthcare
Коэффициент P/B для Veracyte, Inc. (VCYT)
Коэффициент P/B на October 2026 TTM: 2.50
Согласно последним финансовым отчетам и цене акций Veracyte, Inc., текущий коэффициент P/B (TTM) составляет 2.50. В конце 2023 он составлял 1.91.
История P/B для Veracyte, Inc. с 2011 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 2.50 | -3.24% |
| 2024 | 2.58 | 34.57% |
| 2023 | 1.91 | 21.21% |
| 2022 | 1.58 | -38.10% |
| 2021 | 2.55 | -58.76% |
| 2020 | 6.19 | 14.98% |
| 2019 | 5.38 | -7.87% |
| 2018 | 5.84 | -1.88% |
| 2017 | 5.95 | 58.90% |
| 2016 | 3.75 | 2.76% |
| 2015 | 3.64 | -27.86% |
| 2014 | 5.05 | 372.94% |
| 2013 | 1.07 | -97.22% |
| 2012 | 38.38 | 74.05% |
| 2011 | 22.05 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 4.7411 | 89.93% |
US
|
|
| 3.0143 | 20.75% |
US
|
|
| 31.051 | 1,143.88% |
US
|
|
| - | - |
CN
|
|
| 6.6641 | 166.96% |
US
|
